Thelansis

  Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic condition in which the liver's tiny bile ducts become damaged, inflamed, and eventually destroyed. Bile is a fluid made in the liver. It aids digestion and helps the body eliminate toxins, cholesterol and worn-out red blood cells. When the bile ducts are harmed, bile can back up in the liver, causing irreversible scarring of the liver tissue (cirrhosis). The continuous destruction of small and medium bile ducts is mediated by activated CD4 and CD8 lymphocytes. The prevalence of PBC has been estimated to be approximately 51 to 65 cases per 100,000 population in the United States. Thelansis’s “Primary Biliary Cholangitis (PBC) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, ...